Filtered By:
Drug: Colcrys

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 87 results found since Jan 2013.

Colchicine-new horizons for an ancient drug
Eur J Intern Med. 2021 Oct 14:S0953-6205(21)00332-0. doi: 10.1016/j.ejim.2021.10.002. Online ahead of print.ABSTRACTColchicine is an old, inexpensive, and relatively safe anti-inflammatory drug traditionally used in gout and over the last 50 years in familial Mediterranean fever. A search of all high-hierarchy studies (randomized controlled trials [RCTs], systematic reviews and meta-analysis of RCTs) over the last 20 years revealed myriad other evidence-based applications. Colchicine seems efficacious in the treatment of acute pericarditis and prevention of recurrences and the prevention of postcardiac injury syndrome and ...
Source: European Journal of Internal Medicine - October 18, 2021 Category: Internal Medicine Authors: Ami Schattner Source Type: research

Colchicine therapy in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials
Conclusion This meta-analysis suggests that colchicine was not associated with a significant decrease in cardiovascular endpoints and mortality in patients with CAD.
Source: Coronary Artery Disease - July 27, 2021 Category: Cardiology Tags: Reviews and Meta-Analyses in CAD Source Type: research

Safety and Efficacy of Left Atrial Appendage Closure Using an Epicardial Suture Snaring Device: Systematic Review and Current Status
ConclusionsThe LARIAT device is effective in epicardial closure of the left atrial appendage. Improvement in device techniques such as use of micropuncture needle, prophylactic colchicine, and maintenance of a pericardial drain have helped improve safety over time.This article is protected by copyright. All rights reserved.
Source: Journal of Cardiovascular Electrophysiology - June 24, 2021 Category: Cardiology Authors: Syed Rafay Ali Sabzwari, Nikhil A Mehta, Lohit Garg, Lekha Racharla, Emilee Kurtz, Muhammad R Afzal, Mohit K Turagam, Dhanunjaya Lakkireddy Tags: ORIGINAL ARTICLE Source Type: research

Safety and Efficacy of Colchicine in Patients with Stable CAD and ACS: A Systematic Review and Meta-analysis
ConclusionIn patients presenting with ACS, low-dose colchicine might reduce the incidence of MACE, stroke, and the need for revascularization at long follow-up durations. Colchicine might offer no benefits in reducing the risk of ischemic events in patients with stable angina.
Source: American Journal of Cardiovascular Drugs - June 21, 2021 Category: Cardiology Source Type: research

Effects of Colchicine on Cardiovascular Outcomes in Patients with Coronary Artery Disease: A Systematic Review and One-Stage and Two-Stage Meta-Analysis of Randomized-Controlled Trials
ConclusionGiven the significant benefits of colchicine demonstrated on IPD, and its consistent benefits when analyzed using aggregate data meta-analysis, we propose that colchicine may be considered as an additional pharmacological adjunct to the first line therapy for patients with coronary artery disease.
Source: High Blood Pressure and Cardiovascular Prevention - May 18, 2021 Category: Cardiology Source Type: research

Cardiovascular injuries during COVID-19 infection: A PROCESS-compliant case series from the Eastern Morocco
CONCLUSION: Cardiovascular involvement during COVID-19 should not be neglected and are associated with severe outcomes.PMID:33898022 | PMC:PMC8053362 | DOI:10.1016/j.amsu.2021.102309
Source: Annals of Medicine - April 26, 2021 Category: Internal Medicine Authors: Abdelilah El Rhalete Inas Rhazi Amine Bensaid Ikram Zaid Houssam Bkiyer Nabila Ismaili Nouha Elouafi Brahim Housni Source Type: research

Association between Anti-inflammatory Drug and Dementia in Patients with Gout: A Nationwide, Population-Based Nested Case-Control Study
Conclusion: We had identified that > 90-day corticosteroid administration is a significant dementia risk factor in both female and male patients of all ages, especially in the 50-60-year-old group.PMID:33850475 | PMC:PMC8040399 | DOI:10.7150/ijms.55496
Source: International Journal of Medical Sciences - April 14, 2021 Category: Biomedical Science Authors: Natalia Mikhailichenko Yu-Hsun Wang James Cheng-Chung Wei Te-Jen Lai Source Type: research

Colchicine efficacy and safety for the treatment of cardiovascular diseases
AbstractThe emerging role of colchicine in the treatment of cardiovascular diseases is a strong demand for a comprehensive understanding of its efficacy and safety. This meta-analysis and systematic review aimed to study the efficacy in the reduction of adverse cardiovascular outcomes (CO), and the risk of colchicine-related adverse events (CRAEs). Fourteen thousand and nine eighty three patients from 22 randomized controlled trials (RCTs) were included, 9 in patients with coronary artery disease —CAD, 9 in patients with pericarditis, 4 in patients with atrial fibrillation—AF or heart failure. Colchicine was efficaciou...
Source: Internal and Emergency Medicine - March 11, 2021 Category: Emergency Medicine Source Type: research

Update on the Inflammatory Hypothesis of Coronary Artery Disease
AbstractPurpose of ReviewThe pathogenesis and progression of coronary artery disease (CAD) is now known to be largely driven by inflammation on top of the well-accepted role for the disequilibrium between cholesterol deposition and removal from the arterial wall. Recent clinical trials have supported the inflammatory hypothesis of CAD and will be discussed in this review.Recent FindingsThe clinical trial Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) found that treatment with canakinumab, an anti-interleukin-1 β agent, resulted in a reduction in non-fatal myocardial infarction, non-fatal stroke, or death...
Source: Current Cardiology Reports - January 6, 2021 Category: Cardiology Source Type: research

Efficacy and safety of colchicine for secondary prevention of coronary heart disease: a systematic review and meta-analysis
AbstractTo evaluate the efficacy and safety of colchicine for secondary prevention of coronary heart disease (CHD), relevant randomized controlled trials (RCTs) were identified by searching several databases from the creation date to August 31, 2020 and were reviewed. Eight eligible trials of colchicine therapy involving a total of 11, 463 patients were included (5, 776 subjects received colchicine, while 5, 687 subjects were in the respective control arms), and the outcome was reported as risk ratio (RR) and 95% confidence interval (CI), as the relative measure of association. Overall, the incidences of major adverse card...
Source: Internal and Emergency Medicine - January 5, 2021 Category: Emergency Medicine Source Type: research

The Efficacy of Colchicine on Carotid Intima-Media Thickness: A Prospective Comparative Study
Inflammation plays an important role in the development of atherosclerotic vascular disease, which is the leading cause of morbidity and mortality in the adult population. Several clinical trials have shown that suppression of the inflammatory response can delay or decrease the atherosclerotic process. The aim of this study was to investigate carotid intima-media thickness (CIMT) between patients with chronic disease history plus gout using colchicine and patients with cardiovascular risk factors.
Source: Journal of Stroke and Cerebrovascular Diseases - December 30, 2020 Category: Neurology Authors: Ebru Yilmaz, Kadriye Halli Akay Source Type: research

Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes
AbstractHyperuricemia and gout have been linked to an increased risk for cardiovascular (CV) disease, stroke, hypertension, heart failure, and chronic kidney disease, possibly through a proinflammatory milieu. However, not all the drugs used in gout treatment improve CV outcomes; colchicine has shown improved CV outcomes in patients with recent myocardial infarction and stable coronary artery disease independent of lipid-lowering effects. There is resurging interest in colchicine following publication of the COLCOT, LoDoCo, LoDoCo2, LoDoCo-MI trials,  and COLCORONA trial which will shed light on its utility in COVID-19. ...
Source: American Journal of Cardiovascular Drugs - December 28, 2020 Category: Cardiology Source Type: research

Stroke Prevention in Atrial Fibrillation: Looking Forward.
Abstract Ischemic strokes related to atrial fibrillation are highly prevalent, presenting with severe neurologic syndromes and associated with high risk of recurrence. Although advances have been made in both primary and secondary stroke prevention for patients with atrial fibrillation, the long-term risks for stroke recurrence and bleeding complications from antithrombotic treatment remain substantial. We summarize the major advances in stroke prevention for patients with atrial fibrillation during the past 30 years and focus on novel diagnostic and treatment approaches currently under investigation in ongoing cl...
Source: Circulation - December 15, 2020 Category: Cardiology Authors: Katsanos AH, Kamel H, Healey JS, Hart RG Tags: Circulation Source Type: research